VRChat creators have a growing toolkit to craft immersive worlds, with new roadmap features, SDK updates, and design strategies shaping the future of social VR spaces. From Unity basics to advanced ...

Solar accounted for more than 72% of US electrical generating capacity added in 2025, with another 16% from wind, according to belatedly released data from the Federal Energy Regulatory Commission ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

The Federal Reserve's pause on rate cuts means investors can still grab attractive yields on short-duration assets. The central bank opted to keep the federal funds rate between 3.5% to 3.75% on ...

I have been patiently waiting for a buying opportunity in Unity (U), and the apocalypse in software stocks has finally provided one. Sentiment is very low in software as investors appear concerned ...

GameSpot may get a commission from retail offers. Over a decade after a disastrous debut plagued with faceless NPCs and frame rate issues, Assassin's Creed Unity is rounding out its comeback story ...

Creators who post artificial intelligence-generated videos of armed conflicts without clear disclosure will be penalized under new X policies aimed at preventing manipulation and misinformation.

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

A Google patent suggests Search may take you from the results page to a super-personalized AI-generated page that answers your query instead of sending you to a website. Patent. The patent, ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...